share_log

Avenue Therapeutics | 8-K: Current report

Avenue Therapeutics | 8-K: Current report

Avenue Therapeutics | 8-K：重大事件
美股SEC公告 ·  06/26 16:54
Moomoo AI 已提取核心信息
On June 24, 2024, Avenue Therapeutics, Inc. held its annual meeting of stockholders where several key decisions were made. The stockholders approved an amendment to the 2015 Incentive Plan, increasing the number of shares authorized for issuance by 5 million, extending the plan's term to 2034, and raising the annual share limit for non-employee director awards to 500,000. The Board of Directors had previously approved this amendment, which took effect upon stockholder approval. Additionally, six directors were elected to serve until the 2025 annual meeting, and KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2024. The meeting was conducted virtually with a quorum present, representing a majority of the outstanding voting power. The detailed results of the voting on directors, the accounting firm ratification, and the 2015 Plan Amendment were disclosed, with the majority of votes cast in favor of all proposals.
On June 24, 2024, Avenue Therapeutics, Inc. held its annual meeting of stockholders where several key decisions were made. The stockholders approved an amendment to the 2015 Incentive Plan, increasing the number of shares authorized for issuance by 5 million, extending the plan's term to 2034, and raising the annual share limit for non-employee director awards to 500,000. The Board of Directors had previously approved this amendment, which took effect upon stockholder approval. Additionally, six directors were elected to serve until the 2025 annual meeting, and KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2024. The meeting was conducted virtually with a quorum present, representing a majority of the outstanding voting power. The detailed results of the voting on directors, the accounting firm ratification, and the 2015 Plan Amendment were disclosed, with the majority of votes cast in favor of all proposals.
2024年6月24日，Avenue Therapeutics，Inc. 在其股东年度会议上做出了几项关键决定。股东们批准了对2015年激励计划的修正案，将授权发行的股份数量增加了500万股，将计划的期限延长至2034年，并将非雇员董事奖项的年度股份限额提高至500,000股。董事会之前已经批准了这一修正案，股东批准后立即生效。此外，六名董事当选，任期直至2025年的年度会议，KPMG LLP被选为独立的注册会计师事务所，其审核财务报表的截止日期为2024年12月31日。会议以虚拟方式进行，有法定人数的出席，代表了优先投票权的多数。对董事、会计师事务所和2015年计划修正案的投票详细结果亦已公布，大部分投票赞成所有提案。
2024年6月24日，Avenue Therapeutics，Inc. 在其股东年度会议上做出了几项关键决定。股东们批准了对2015年激励计划的修正案，将授权发行的股份数量增加了500万股，将计划的期限延长至2034年，并将非雇员董事奖项的年度股份限额提高至500,000股。董事会之前已经批准了这一修正案，股东批准后立即生效。此外，六名董事当选，任期直至2025年的年度会议，KPMG LLP被选为独立的注册会计师事务所，其审核财务报表的截止日期为2024年12月31日。会议以虚拟方式进行，有法定人数的出席，代表了优先投票权的多数。对董事、会计师事务所和2015年计划修正案的投票详细结果亦已公布，大部分投票赞成所有提案。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息